【摘要】 目的  了解利拉鲁肽对新诊断T2DM患者外周血内皮素-1（ET-1）、一氧化氮（NO）水平的影响及其相关因素。方法  选取新诊断T2DM患者38例，根据颈动脉内-中膜厚度（CIMT）分为无AS（Non-AS，CIMT≤0.9 mm）组22例和A（CIMT＞0.9 mm）组16例，均经利拉鲁肽治疗12周。检测治疗前后外周血ET-1、NO水平，并分析治疗前后外周血ET-1、NO水平改变的相关影响因素。 结果   两组治疗后NO水平[AS组：（89.6±15.8）vs（68.1±14.7）μmol/L；Non-AS组：（113.2±13.4）vs （79.4±11.2）μmol/L]均高于治疗前（P＜0.05），ET-1水平[AS组：（69.8±15.1） vs （99.5±13.6） μmol/L；Non-AS组：（65.7±16.3） vs （82.6±10.9） μmol/L]均低于治疗前（P＜0.05）。外周血NO、ET-1变化值均与ΔBMI、ΔWHR、ΔFPG和ΔHbA₁c相关（P＜0.05）。 结论  利拉鲁肽可提高新诊断T2DM患者外周血NO水平，降低ET-1浓度。

【关键词】 糖尿病，2型；利拉鲁肽；内皮素-1；一氧化氮

 Effect of liraglutide on the circulating levels of endothelin-1 and nitric oxide in patients with newly diagnosed type 2 diabetes

 【Abstract】  Objective  To investigate the effect of liraglutide on the circulating levels of endothelin-1 and nitric oxide in patients with newly diagnosed type 2 diabetes（T2DM） and their related factors.  Methods  A total of 38 patients with newly diagnosed T2DM were selected and divided into two groups according to carotid intima-media thickness (CIMT): Non-AS group (CIMT≤0.9 mm, n=22) and AS group (CIMT＞0.9 mm, n=16). All patients were treated with liraglutide for 12 weeks. The circulating levels of endothelin-1 and nitric oxide were measured before and after treatment and the influencing factors of their changes were analyzed.  Results  After liraglutide treatment, the circulating levels of nitric oxide significantly increased in both groups[(89.6±15.8) vs （68.1±14.7） μmol/L for AS group；(113.2±13.4) vs (79.4±11.2) μmol/L for Non-AS group; P＜0.05], and the circulating levels of endothelin-1 significantly decreased in both groups [(69.8±15.1) vs (99.5±13.6) μmol/L for AS group; (65.7±16.3) vs (82.6±10.9) μmol/L for Non-AS group; P＜0.05]. Correlation analysis showed that changes of circulating levels of endothelin-1 and nitric oxide were correlated with ΔBMI, ΔWHR, ΔFPG and ΔHbA₁c (P＜0.05).  Conclusion  Liraglutide can increase the circulating levels of nitric oxide and decrease the levels of endothelin-1 in patients with newly diagnosed T2DM.

【Key words】  Diabetes mellitus, type 2; Liraglutide; Endothelin-1; Nitric oxide（NO）